Skip to main content

Market Overview

Berenberg Downgrades Bristol-Myers Squibb, Says Competitors Better Exposed For Near-Term Upside


Bristol-Myers Squibb Co’s (NYSE: BMY) CheckMate 026 trial to evaluate IO drug Opdivo for monotherapy in first-line NSCLC in PD-Li positive patients has ended in failure.

Berenberg’s Laura Sutcliffe downgraded the rating on the company from Buy to Hold, while lowering the price target from $80 to $70.

Failed Trial

“While a lack of success in this particular trial has no impact on about half of Bristol’s IO opportunity, it affects the NSCLC space as a whole, and places Bristol on the back foot in a market where it has, up until now, dominated.,” Sutcliffe explained.

The analyst pointed out that despite Opdivo not having an indication as monotherapy in first-line NSCLC, Bristol-Myers Squibb has reported some off-label use, which is likely to cease following the failure of the trial.

Related Link: Argus: Bristol-Myers Selloff Is Overdone, Reiterating $90 Target

Lagging The Competition

The next major trial for Opdivo will focus on combination therapy, with the company’s CheckMate 227 trial focusing on IO-IO and IO-chemo combinations.

However, Sutcliffe noted that Bristol-Myers Squibb was behind the competition on this, with some of its major competitors scheduled to report IO-chemo data in 2017.

The analyst now expects Opdivo to account for 30 percent of the company’s sales in 2020, down from the earlier 35 percent.

The EPS estimate for FY16 has been lowered from $2.65 to $2.58.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for BMY

Nov 2020Societe GeneraleUpgradesHoldBuy
Nov 2020BernsteinReinstatesMarket Perform
Oct 2020Truist SecuritiesInitiates Coverage OnHold

View More Analyst Ratings for BMY
View the Latest Analyst Ratings


Related Articles (BMY)

View Comments and Join the Discussion!

Posted-In: Berenberg Laura SutcliffeAnalyst Color Downgrades Health Care Price Target Analyst Ratings General

Latest Ratings

GDWolfe ResearchDowngrades
QRTEAB of A SecuritiesInitiates Coverage On
ABB of A SecuritiesDowngrades42.0
VCTRB of A SecuritiesUpgrades32.0
BSIGB of A SecuritiesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at